» Articles » PMID: 24673454

Impaired Proplatelet Formation in Immune Thrombocytopenia: a Novel Mechanism Contributing to Decreased Platelet Count

Overview
Journal Br J Haematol
Specialty Hematology
Date 2014 Mar 29
PMID 24673454
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The pathophysiological mechanisms contributing to the decreased platelet count in immune thrombocytopenia (ITP) are not entirely understood. Here, we investigated the key step of proplatelet formation (PPF) by studying the effect of ITP plasma in thrombopoiesis. Normal cord blood-derived mature megakaryocytes were cultured in the presence of recalcified plasma from ITP patients, and PPF was evaluated by microscopic analysis. Patient samples induced a dose-dependent inhibition in PPF, as well as decreased complexity of proplatelet architecture. Although slightly increased, plasma-induced megakaryocyte apoptosis was not related to PPF impairment. Purified IgG reproduced the inhibitory effect, while platelet-adsorbed plasma induced its reversion, suggesting the involvement of auto-antibodies in the inhibition of thrombopoiesis. Impaired PPF, induced by ITP plasmas bearing anti-GPIIb-IIIa antibodies, was related to their ability to interfere with the normal function of this integrin, as assessed by megakaryocyte PAC-1 binding and β3 integrin phosphorylation while the presence of anti-glycoprotein Ia-IIa auto-antibodies was associated with loss of normal inhibition of PPF induced by type I collagen. In conclusion, abnormal thrombopoiesis comprising decreased PPF and morphological changes in proplatelet structure are induced by patient samples, unveiling new mechanisms contributing to decreased platelet count in ITP.

Citing Articles

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia.

Evangelidis P, Tragiannidis K, Gavriilaki E, Tragiannidis A Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852180 PMC: 11763769. DOI: 10.3390/cimb47010065.


Desialylation and Apoptosis in Immune Thrombocytopenia: Implications for Pathogenesis and Treatment.

Zheng S, Perdomo J Curr Issues Mol Biol. 2024; 46(11):11942-11956.

PMID: 39590303 PMC: 11592706. DOI: 10.3390/cimb46110709.


Immune attack on megakaryocytes in immune thrombocytopenia.

Petito E, Gresele P Res Pract Thromb Haemost. 2024; 8(1):102345.

PMID: 38525349 PMC: 10960061. DOI: 10.1016/j.rpth.2024.102345.


A Novel Antithrombocytopenia Agent, , Promotes Megakaryopoiesis and Thrombopoiesis through the PI3K/AKT, MEK/ERK, and JAK2/STAT3 Signaling Pathways.

Chen W, Zhu L, Wang L, Zeng J, Wen M, Xu X Int J Mol Sci. 2022; 23(22).

PMID: 36430539 PMC: 9694118. DOI: 10.3390/ijms232214060.


Investigation of the correlation between immune thrombocytopenia and T cell activity-regulated gene polymorphism using functional study.

Chen D, Lin W, Wen Y, Wang W Sci Rep. 2022; 12(1):6601.

PMID: 35459882 PMC: 9033768. DOI: 10.1038/s41598-022-10631-z.